Publications and Presentations

Corvus is committed to driving science and medicine and helping patients. We promptly and efficiently communicate our preclinical and clinical findings to the scientific, medical and patient communities because we believe disseminating knowledge and information is good for patients.

Our scientists and clinical trial investigators have published the following research papers in peer-reviewed journals and presented the following data at scientific congresses.

Presentations


Interleukin-2-Inducible T-cell Kinase Inhibitors for the Treatment of T-cell Lymphoproliferative Disorders

John C. Reneau, MD, PhD1, Steven R. Hwang, MD2, Carlos A. Murga-Zamalloa, MD1, Joseph J. Buggy, PhD3, James W. Janc, PhDand Ryan A. Wilcox, MD, PhD1

University of Michigan, Ann Arbor, MI; 2 Mayo Clinic, Rochester, MN; 3 Corvus Pharmaceuticals, Inc., Burlingame, CA

Poster presentation at 60th Annual ASH Meeting, San Diego, CA, Dec 1-4th 2018


CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor Has Clinical Activity in Dogs with Spontaneous T-cell Lymphoma

Douglas H. Thamm,1 Kristen M. Weishaar,1 Sunetra Das,1 Antonett Madriaga,2 Craig M. Hill,2 Felicia M. Flicker,2 Bradley H. Wolfe,2 Patrick P. Ng,2 Andrew N. Hotson,2 Richard A. Miller,2 Joseph J. Buggy,2 James W. Janc2

Flint Animal Cancer Center, Colorado State University, Fort Collins, CO USA; Corvus Pharmaceuticals, Burlingame, CA USA

Poster presentation at 30th EORTC-NCI-AACR Symposium, Molecular Targets and Cancer Therapeutics, Dublin IE, Nov 13-16th 2018


Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444

Lawrence Fong, M.D., University of California, San Francisco

Oral presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting


Preclinical and initial Phase I clinical characterization of CPI-006: an anti-CD73 monoclonal antibody with unique immunostimulatory activity

Emily Piccione, Ph.D., Corvus Pharmaceuticals

Poster presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting


Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444

Drew Hotson, Ph.D., Corvus Pharmaceuticals

Poster presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting


Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

Willingham S1, Hotson A1, Laport G1, Kwei L1, Fong L2, Sznol M3, Powderly J4, Miller R1

Corvus Pharmaceuticals, Burlingame CA, USA, 2 University of California, San Francisco CA, USA, Yale University School of Medicine, New Haven CT, USA, Carolina BioOncology Institute, Huntersville NC, USA

Poster presentation at 2018 European Society for Medical Oncology (ESMO) 2018 Congress


Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

Stephen Willingham, Ph.D., Corvus Pharmaceuticals

Slide presentation at 2018 European Society for Medical Oncology (ESMO) 2018 Congress


Preclinical Study of Investigational Small Molecule T-cell Signaling Pathway Inhibitor in Companion Dogs Diagnosed with T-cell Lymphoma

Ryan Wilcox, M.D., Ph.D., Assistant Professor at the University of Michigan Comprehensive Cancer Center

Oral presentation at 10th Annual T-Cell Lymphoma Forum (2018)


Clinical Activity of Adenosine A2a Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation

Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, University of Chicago Medicine

Oral presentation at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (2017)


Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

Lawrence Fong, M.D., Leader, Cancer Immunotherapy Program, Co-Director, Parker Institute of Cancer Immunotherapy, University of California, San Francisco

Oral presentation at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting


CPI-444, an oral adenosine A2a receptor (A2AR) antagonist, demonstrates clinical activity in patients with advanced solid tumors 

Leisha Emens, M.D., Ph.D., Associate Professor of Oncology, John Hopkins Sidney Kimmel Comprehensive Cancer Center

Oral Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting


Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies

Stephen Willingham, Ph.D., Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting


Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models

Po Y. Ho, Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting


A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T-cell function

Emily Piccione, Ph.D., Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting


Publications

The following contains links to certain websites owned and operated by third parties. If you use these links you leave our website. These links are provided for your information and convenience only and are not an endorsement by Corvus Pharmaceuticals, Inc. of the content of such linked websites. Corvus has no control of the content of any linked website and is not responsible for these websites or their content or availability. Corvus therefore makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by or the information contained on them.

Our Science

We are developing oncology medicines with differentiated mechanisms of action directed at precisely-defined molecular targets

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer